This is a potentially transformative clinical readout for Precision BioSciences, providing the first-ever clinical proof-of-concept for direct cccDNA elimination in hepatitis B. The 100% pgRNA loss rate and biopsy confirmation of mechanism are best-in-class signals. Monitor for partnership interest, additional biopsy data, and Part 2 expansion details by year-end 2026. The manageable safety profile with implemented mitigation measures reduces clinical risk.
Price Chart
Executive Summary
Precision BioSciences announced new and late-breaking clinical data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV in chronic hepatitis B at the EASL Congress 2026. Liver biopsy data showed a 1-log (10-fold) reduction in cccDNA-derived transcripts, the first-ever clinical evidence of direct cccDNA elimination by a therapeutic agent, and 100% of patients with detectable pgRNA at baseline achieved pgRNA loss. The safety profile was manageable with no dose-limiting toxicities, though Grade 3 hypotension and ALT/AST abnormalities were observed and mitigated with protocol adjustments.
Key Facts
- Liver biopsy data demonstrated a 1-log (10-fold) reduction in cccDNA-derived transcripts after two doses at 0.4 mg/kg, the first clinical evidence of direct cccDNA elimination by a therapeutic agent.
- PBGENE-HBV achieved pgRNA loss in 100% of patients (n=6) with detectable pgRNA at baseline, with complete loss of blood pgRNA corresponding to undetectable pgRNA in post-treatment liver biopsy.
- 100% of patients (n=15) experienced substantial HBsAg declines across all dose levels, with durable response ranging from 1.5 to 12+ months in patients who received repeat administrations (n=13).
- As of data cutoff (May 4, 2026), 38 doses were administered across 16 patients in 5 cohorts; no dose-limiting toxicities were observed.
- Grade 3 hypotension and reversible ALT/AST abnormalities were observed but mitigated with slower infusion rates and increased steroid doses; no Grade 3 events occurred after mitigation protocol implementation in up to 20% of doses.
- PBGENE-HBV has FDA Fast Track designation; next update expected by end of 2026 with expansion into Part 2 of the trial.
Financial Impact
No financial figures reported; clinical-stage company with no revenue from PBGENE-HBV. Positive clinical data could significantly increase probability of regulatory success and partnership value.
Risk Factors
- Small sample size (n=16) limits statistical robustness; results may not replicate in larger populations.
- One patient in the highest dose cohort (0.8 mg/kg) experienced two serious adverse events, including a treatment-related hypotension event.
- Long-term durability of viral cure and functional cure endpoints (HBsAg loss, nucleoside analog withdrawal) remain unproven.
- Competing gene editing and antiviral approaches may achieve similar or better results.
- Company has no approved products and relies on capital markets for funding; positive data may accelerate but does not eliminate financing risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-038307 |
| Document: a05272026ex991.htm | 0001628280-26-038307 |
| Document: 0001628280-26-038307-index-headers.html | 0001628280-26-038307 |
| Document: 0001628280-26-038307-index.html | 0001628280-26-038307 |
| Document: 0001628280-26-038307.txt | 0001628280-26-038307 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 5w ago | Institutional Cluster | $7.19 $6.36 | ▼ −11.54% | ▼ −10.82% | $6.75 (−6.12%) |
Aug 24, 2026 9w ago | 8-K | $8.45 $8.55 | ▲ +1.18% | ▲ +0.86% | $6.75 (−20.12%) |
Aug 6, 2026 11w ago | 8-K | $7.42 $7.49 | ▲ +0.94% | ▲ +0.33% | $6.75 (−9.03%) |
Jul 27, 2026 13w ago | 8-K | $7.25 $7.17 | ▼ −1.10% | ▼ −1.34% | $6.75 (−6.90%) |
Jul 1, 2026 16w ago | 8-K | $7.88 $8.18 | ▲ +3.81% | ▲ +3.94% | $6.75 (−14.34%) |
Jun 16, 2026 18w ago | 8-K | $6.50 $6.81 | ▲ +4.77% | ▲ +3.99% | $6.75 (+3.85%) |
May 27, 2026 21w ago | 8-K | $7.59 $6.92 | ▼ −8.83% | ▼ −9.38% | $6.75 (−11.07%) |
May 26, 2026 21w ago | 8-K | $7.59 $6.92 | ▼ −8.83% | ▼ −9.38% | $6.75 (−11.07%) |
May 5, 2026 25w ago | 8-K | $7.45 $7.52 | ▲ +0.94% | ▼ −0.45% | $6.75 (−9.40%) |
Apr 8, 2026 28w ago | DEFA14A | $5.99 $6.61 | ▲ +10.35% | ▲ +9.78% | $6.75 (+12.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers